Innovation at Work
Rhode Island

Total Direct and Indirect Economic Output of the Biopharmaceutical Sector
$4.9 billion

Total Employment Supported by the Biopharmaceutical Sector
17,330

Rhode Islanders with diabetes
106,210

Total NIH Award Funding (FY17)
$170 million

Local Perspective: Warwick, RI
"Diabetes is considered a disability, I don’t see my life as living with a disability. I see it as “this ability” to do great things. Supporting research like I have, will help save the lives of millions nationwide.”
-Zachary

Warwick, RI
Zachary and Ava Librizzi, living with Type 1 diabetes

A majority of Americans agree that even if it brings no immediate benefits, basic scientific research that advances the frontiers of knowledge is necessary and should be supported by the federal government.

Research in the Ocean State

Lifespan, Riverside, RI
Lifespan, in partnership with Bradley Hospital in Riverside, Rhode Island, is conducting a clinical trial to study the effect of transcranial direct stimulation (tDCS) on the brain pathways associated with impulsivity in suicidal adolescents. Impulsivity is a risk factor for suicide in adolescents, and this treatment could serve as a possible preventative therapy for at risk teenagers.

University of Rhode Island (URI), South Kingston, RI
National Institutes of Health (NIH)-funded URI researchers are working to combat alcohol dependence, which affects approximately 10% of adults in the U.S. The study builds on previous research focused on moderating the craving for alcohol.

Brown University, Providence, RI
Patients with schizophrenia are at an increased of cigarette smoking-related morbidity and mortality. Brown University researchers are investigating the impact of varenicline, a smoking cessation drug, as well as behavioral interventions for smokers with schizophrenia.

Sources: National Institutes of Health (NIH), Pharmaceutical Research and Manufacturers of America (PhRMA), Centers for Disease Control and Prevention (CDC), A Research!America Survey of U.S. Adults conducted in partnership with Zogby Analytics in January 2017, ClinicalTrials.gov.